It shouldn’t come as a surprise that biopharma in China is growing faster than many in the West have projected. A number of economic and development factors are contributing to this growth. But these have all been evolving for decades. 

So if there is a gap in Western (and in some cases China’s own internal) knowledge about this evolution, it should be put down to simply not paying enough attention.  

The next generation sequencing (NGS) market has captured the interest of many companies and investors across a variety of applications including clinical diagnostics, drug discovery and development, forensics, and consumer genomics, to name a few.

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a variety of important cellular functions. One of their important functions is to transfer DNA, RNA, and proteins to other cells.

For years, exosomes were considered to be transporters of cellular waste, but now they are becoming recognized for their critical role in cell-to-cell communication and transportation.

According to a market research report by BIS Research titled "Global Precision Medicine Market – Analysis and Forecast (2017-2026)," the global precision medicine market is expected to reach a value of $141.7 billion by the year 2026, wherein the oncology market segment is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2017 to 2026.

3D bioprinting artificially constructs living tissue by applying layer-upon-layer of living cells. The deposition of live cells in combination with biological substances such as collagen, fibrin, and gelatin supports the growth of complete tissues and organs.

MarketResearch.com has five in-house publishing divisions that produce quality market intelligence for top industry decision makers. 

These publishers not only provide market research reports, they have also released a number of free white papers, presentations, and e-books on a variety of dynamic markets. These resources are designed to give you a quick view of an industry, leading companies, or trends. 

Kalorama Information, a leading healthcare market research firm, just released a new e-book titled 15 Biotech Companies to Watch. This free resource covers a variety of innovative biotechnology companies and provides detailed information on novel products, emerging technologies, and M&A activity.

I caught up with Bruce Carlson, the Publisher of Kalorama Information, to hear more about the e-book and the biotechnology industry as a whole. Read the Q&A below for his unique insights into this rapidly evolving sector.

The field of gene editing is expanding rapidly. A team of scientists in China recently injected CRISPR-edited cells into a human patient for the first time — potentially setting off a biomedical race between China and the United States, as reported in the international scientific journal Nature.

More significant developments are expected in the years to come. The global CRISPR market is forecast to grow at an astonishing compound annual growth rate (CAGR) of 35% from 2016 to 2022, according to Inkwood Research, a market intelligence firm. The number of scientific papers published on CRISPR continues to soar, from below 200 papers in 2012 to more than 1,200 papers in 2015.

Recently, there has been a lot of buzz around a “new” tool that scientists have found to perform genetic manipulation that is referred to as CRISPR/Cas. The ability to edit DNA has been available for quite some time, so what makes this method special? The answer lies in what it is and how well it works.

What Is CRISPR?

CRISPR is an acronym that stands for “clustered regularly interspaced short palindromic repeats.” It is not actually a technology; it is a natural DNA sequence found in bacteria. So why do we care about bacterial DNA? What scientists have discovered is that there is a part of the bacterial DNA where DNA sequences would show up over and over and, in between those duplicate sequences, there were more unique sequences that matched the viruses that the bacteria had run into in the past. The bacteria use those unique sequences to identify the viruses that are a threat so they can defend themselves much like an immune system.

To compete in the global cord blood banking marketplace, you need to be informed about major market forces, including clinical trial data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving industry, those who choose to commit to understanding current conditions will be positioned for a substantial strategic advantage.

Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. Read on to learn more.